Domainex
No Reviews Yet
2 Orders Completed
Saffron Walden, GB
Domainex is a drug discovery company with a reputation for speed and innovation built on an exceptional track record of drug candidate delivery. It has a world class discovery team with an unrivalled track record and three client drug candidates already in clinic.
Domainex reduces industry average drug discovery timelines by as much as 30% through the application of novel proprietary technologies and a highly focussed and integrated approach to medicinal chemistry and computational chemistry. These technologies and Domainex’s approach also enable it to successfully tackle a greater range of drug target classes, such as kinases, proteases, ion channels, proteins involved in epigenetics and protein-protein interactions.
Domainex has applied its unique technologies and focussed discovery approach to enable it to develop its own pipeline of oncology drugs, including inhibitors of the kinases IKKε/TBK1 and a number of epigenetics related lysine methyltransferases.
Domainex is able to offer seamless support of its clients' DMPK testing requirements within its laboratories in Cambridge. Its capabilities include a wide range of in vitro tests, including:
Via its closely located partner, Pharmidex, Domainex is also able to offer the full range of ADMET assays; as listed below. Domainex and Pharmidex have built up an excellent working relationship over a number of years and both companies work together to ensure speed and efficiency at all stages of a client's discovery programme.
Pharmidex's offering includes, but is not limited to:
FragmentBuilder - identifying higher quality lead compounds
If you have a pure and well-characterised protein, fragment screening offers a practical and cost-effective alternative to traditional high-throughput screening methods. Our high-throughput fragment-based drug discovery services are designed to provide you with high quality lead compounds at a speed and quality not matched by our competitors.
Exclusive fragment library
Your search needs to be thorough and efficient. That’s why the fragment-based drug discovery team at Domainex have used their significant experience in drug discovery to build their own high quality and unique collection of chemical fragments. The 1,000 fragment library has been designed to provide good coverage of the ‘ideal fragment space’. The diverse range of pharmacophores make it the ideal starting point for your next drug candidate.
Innovative screening
Domainex is the first contract research organisation in the UK to offer automated MicroScale Thermophoresis (MST) as part of our fragment-based drug discovery services. The high-throughput technique quantifies molecular interactions and structural dynamics, to present binding affinity results in just a few minutes. There are many reasons we think MST offers many advantages over alternative molecular interaction assay methods:
It’s quick
It’s sensitive
It’s efficient
Small sample consumption (fragment screening using as little as 400µg of protein)
Just the beginning…
We’re confident that our exclusive fragment library and screening techniques will provide you with high quality hit compounds. But that is just the beginning. We can identify soluble domains using our proprietary Combinatorial Domain Hunting platform, and transform hit molecules into clinical candidates using the skills and experience of our medicinal and computational chemists.
Expertise in computational chemistry can significantly improve the efficiency of drug discovery, especially when it is well integrated with a dynamic medicinal chemistry team, as at Domainex. The ongoing development of theoretical models, based on the most up-to-date results, ensures that scientists have the best opportunity of designing relevant novel chemical entities. Domainex offers expertise in a range of computational chemistry solutions including:
Hit finding through our proven LeadBuilder approach
This includes the virtual screening of our Lead-like (NICE) database using a combination of pharmacophore-based and structure-based techniques (such as docking). See 'LeadBuilder' for more information.
Scaffold hopping
Through techniques such as de novo design and similarity searching, we are able to identify patent-busting scaffolds and compounds.
Ligand-Based Drug Design
Using the existing knowledge of known active compounds, we can generate information-rich models containing pharmacophore features that are common to many of the known ligands. These models can then be used in Virtual Screening to search a database of compounds.
Structure-based drug design (SBDD)
By visualizing and analyzing models based on structural data, we are able to assist scientists in the rational design and development of novel molecules that bind to the biological target of interest.
Domainex is able to establish useful homology models for drug targets where there is no existing crystal structure information available, or to complete structural studies in order to resolve novel structures.
By visualizing and analyzing models based on structural data, we are able to assist scientists in the rational design and development of novel molecules that bind to the biological target of interest.
Domainex is able to establish useful homology models for drug targets where there is no existing crystal structure information available, or to complete structural studies in order to resolve novel structures.
Domainex provides high-quality medicinal chemistry services and synthetic chemistry services that efficiently progress drug discovery projects from hit identification through lead generation and optimization, to the nomination of effective drug candidates. Our medicinal chemists have extensive experience in developing drug candidates against a broad range of target disease indications, which has provided us with one of the best track records in the industry; with an average of one candidate drug nominated every year!
Supported by our computational chemistry expertise and BioassayBuilder platform, Domainex will design and provide a medicinal chemistry programme tailored to your specific requirements. Our “every compound counts” philosophy means that we take into account all the relevant properties including biological activity, selectivity, pharmacokinetic (i.e. ADME) and toxicology properties in parallel, as well as patentability, in the design of your compounds.
Domainex can help with all aspects of hit-to-candidate activities including:-
Domainex has an established track record in a diverse range of target and ligand classes, including:-
Our medicinal chemistry services can be integrated with our computational chemistry, structural biology, protein expression, ADMET/PK and BioassayBuilder services to provide you with a comprehensive drug discovery solution.
BioassayBuilder is a suite of bioassay services, from protein expression to characterisation of pre-clinical candidates. Our team of experienced molecular, assay and cell biologists are able to support you in a way precisely adapted to your needs. Whether you have specific requirements or are looking for a partner to provide a full range of support, covering for instance:
Our specialists will work with you from initial discussions through to project completion and be ready to adapt to your changing needs and nature of the results as they emerge.
Key features & deliverables of the Domainex BioassayBuilder services are:
The availability of sufficient protein of good quality can be rate limiting for many drug discovery programmes, as a lack of target protein supply can hamper the ability to establish hit screening assays and to complete structural studies.
As part of our BioassayBuilder platform, Domainex's biology team is able to clone, express and purify your proteins of interest and can produce protein at the required levels for ongoing biochemical compound screening or structural studies, extremely quickly, whether in E. coli or insect cells, up to the 12 L or 5 L scale respectively.
Domainex's scientists' experience is broad and they have successfully provided protein for a wide range of drug discovery programmes, including, but not limited to: kinases, proteases, protein-protein interactions, protein methyltransferases and demethylases. In cases where standard bioinformatics or literature-informed molecular biology approaches are not appropriate, Domainex is able to offer its proprietary high throughput cloning technology, Combinatorial Domain Hunting (CDH), which quickly enables the screening of 30,000-100,000 different gene constructs of a given target protein.
Hit Identification Services
Pharmacology Services
Pharmacology & Toxicology Services
Protein Services
Structural Biology Services
Biochemistry & Molecular Biology Services
Biology Services
Domainex has not received any reviews.
Domainex has not received any endorsements.